News|Articles|November 19, 2026

sNDA Submitted: Caplyta for the Treatment of Bipolar Mania

Author(s)Leah Kuntz
Listen
0:00 / 0:00

Key Takeaways

  • Johnson & Johnson is pursuing a fifth adult indication for lumateperone, extending its current approvals in schizophrenia, bipolar depression, and adjunctive major depressive disorder.
  • Two pivotal phase 3 trials (studies 451 and 452) evaluated lumateperone 42 mg once daily versus placebo for 3 weeks in bipolar I mania, with or without mixed features.
SHOW MORE

Johnson & Johnson has submitted an sNDA to the FDA for Caplyta for the treatment of bipolar mania.

Johnson & Johnson has announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for the approval of lumateperone (Caplyta) as a treatment of manic or mixed episodes associated with bipolar I disorder in adults. The submission is supported by 2 pivotal phase 3 studies in which Caplyta significantly reduced manic symptoms compared with placebo as early as day 3, with improvement sustained through week 3. If approved, bipolar mania would become the fifth approved use for Caplyta in adults.1

Caplyta is an oral, once daily atypical antipsychotic approved by the FDA in adults for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy or as adjunctive therapy with lithium or valproate; for the treatment of schizophrenia; and as adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD). While the mechanism of action of CAPLYTA is unknown, the efficacy of CAPLYTA could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors.

"For people experiencing acute mania, rapid symptom improvement and tolerability are both critical treatment considerations," said John C. Reed, MD, PhD, the executive vice president, Innovative Medicine, R&D, Johnson & Johnson. "Our phase 3 results demonstrate the potential for Caplyta to address these needs, and this submission advances our ambition to provide a foundational treatment that can support patients across the evolving course of serious psychiatric disorders."

Phase 3 Studies

Positive results from study 451 and study 452 form the basis of the sNDA submission. These 2 studies were randomized, double-blind, placebo-controlled studies of once-daily Caplyta 42 mg vs placebo in adults with manic episodes, with or without mixed features, associated with bipolar I disorder. In each study, participants were randomly assigned to receive once-daily lumateperone 42 mg or placebo for 3 weeks. The primary endpoint of each study was change from baseline in Young Mania Rating Scale (YMRS) total score at week 3, and the key secondary endpoint was change from baseline in Clinical Global Impression–Severity (CGI-S) score at week 3.

In both studies, Caplyta met the primary and key secondary endpoints, demonstrating significant and rapid improvement in bipolar mania symptoms and overall illness severity vs placebo. Improvement in manic symptoms was observed as early as day 3, following 2 days of treatment. Caplyta was well tolerated, with low rates of discontinuation and a safety profile consistent with prior studies.2,3

About Bipolar Mania

According to estimates, 11 million US adults experience bipolar disorder at some point in their lives.4 Mania symptoms can include grandiosity, decreased need for sleep, racing thoughts, distractibility, and risk-taking behavior.5 Manic episodes can escalate quickly, often requiring the patient to be hospitalized for safety and treatment. Rapid and sustained control of manic symptoms remains an important treatment goal in the management of bipolar I disorder.

References

1. Johnson & Johnson seeks U.S. FDA approval for CAPLYTA in bipolar mania, marking fifth potential indication. News release. November 19, 2026. Accessed November 19, 2026. https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-Seeks-U-S--FDA-Approval-for-CAPLYTA-in-Bipolar-Mania-Marking-Fifth-Potential-Indication/default.aspx

2. Cutler AJ, Earley WR, Hayes R, et al. Lumateperone treatment of manic episodes with or without mixed features in bipolar I disorder: results from a double-blind, placebo-controlled, randomized, phase 3 trial. Posted presented at: Psych Congress 2026; September 15-19, 2026.

3. McIntyre RS, Earley WR, Hayes R, et al. Lumateperone for the treatment of bipolar mania in patients with bipolar I disorder: results from a double-blind, placebo controlled, randomized, phase 3 trial. Posted presented at: NEI Fall Congress 2026; November 5-8, 2026.

4. Bipolar disorder. National Institute of Mental Health. Accessed November 19, 2026. https://www.nimh.nih.gov/health/statistics/bipolar-disorder

5. Oliva V, Fico G, De Prisco M, et al. Bipolar disorders: an update on critical aspects. Lancet Reg Health Eur. 2024;48:101135.




Related to this article